Filing Details

CUSIP No.  18978W109

¹ The shares do not include (a) up to 11,597,198 Earn-Out Shares (as described in Item 3 of Reporting Persons’ Schedule 13D filed October 13, 2021.

² Based on the number of shares of Class A Common Stock of Issuer (as defined below) issued and outstanding at April 29, 2022.

CUSIP No.  18978W109

This Amendment No. 2 ("Amendment No. 2") to Schedule 13D relates to the Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), of Sema4 Holdings Corp. ("Sema4" or "Issuer"), and amends and supplements the Schedule 13D, filed October 13, 2021, as amended by Amendment No. 1, filed January 21, 2022 ("Amendment No. 1" and as amended, the "Schedule 13D") by Icahn School of Medicine at Mount Sinai ("ISMMS") and Mount Sinai Health System, Inc. ("MSHS"). As of April 29, 2022, following closing of the transactions described in Issuer's Current Report on Form 8-K (referenced in Item 4 below), the issued and outstanding Class A Common Stock of Sema4 totalled 377,249,186 shares. The principal executive office of Sema4 is located at 333 Ludlow Street, North Tower, 8th Floor, Stamford, Connecticut 06902.

Item 2 of this Amendment No. 2 incorporates herein by reference the information set forth in Item 2 of the Schedule 13D.

 Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

The information set forth in Item 4 of this Amendment No. 2 is hereby incorporated by reference into this Item 3.

Item 4 is hereby amended and supplemented as follows:

As disclosed by Issuer in a Current Report on Form 8-K filed May 2, 2022 (the "Form 8-K"), Issuer closed the mergers described in that certain Agreement and Plan of Merger and Reorganization, dated January 14, 2021, with GeneDx, Inc. ("GeneDx"), a wholly-owned subsidiary of OPKO Health, Inc. ("OPKO"), GeneDx Holding 2, Inc., and OPKO (the "GeneDx Merger Agreement"), and as contemplated thereby, GeneDx became a wholly-owned indirect subsidiary of Issuer (the "Closing").

As described in Amendment No. 1, concurrently with the Closing, as part of a $200 million private placement of Class A Common Stock (the "PIPE") of Issuer, ISMMS purchased from Issuer 6,250,000 shares of Class A Common Stock (the "PIPE Shares") at a purchase price of $4.00 per share for the aggregate purchase price of $25 million.

The information in Item 3 of this Amendment No. 2 is incorporated by reference into this Item 4. The Reporting Persons expect to evaluate on an ongoing basis the Issuer's financial condition and prospects and their respective interests in, and intentions with respect to, the Issuer and their respective investments in the securities of Issuer, which review may be based on various factors, including Issuer's business and financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for Issuer's securities in particular, as well as other developments and other investment opportunities. Accordingly, each Reporting Person reserves the right to change its intentions, as it deems appropriate. In particular, each Reporting Person may, at any time and from time to time, in the open market, in privately negotiated transactions or otherwise, increase its holdings in Issuer or dispose of all or a portion of the securities of Issuer that such Reporting Person now owns or may hereafter acquire, including sales pursuant to the exercise of the registration rights provided for in the Subscription Agreements described in Amendment No. 1.

Except as described in this Amendment No. 2, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, subject to the agreements described herein, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the board of Issuer with respect to the business and affairs of Issuer and may from time to time consider pursuing or proposing such matters with advisors, Issuer or other persons.

Item 5 of the Schedule 13D is hereby amended and restated as follows:

(a) and (b)          Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 2 are incorporated herein by reference. Calculation of the percentage of shares of Class A Common Stock beneficially owned assumes that there were 377,249,186 shares of Class A Common Stock issued and outstanding following the Closing and the PIPE, as reported by Issuer in the Registration Statement on Form S-1 filed on May 3, 2022. Shares of Class A Common Stock owned by ISMMS include the following:

88,355,473				Shares Reported in the Schedule 13D
6,250,000				PIPE Shares Acquired as of April 29, 2022

MSHS disclaims beneficial ownership over all Shares beneficially owned by ISMMS, other than for the purpose of determining obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this Amendment No. 2 shall not be deemed an admission that MSHS is the beneficial owner of such securities for any other purpose.

The information set forth in Items 2, 3, 4 and 5 is hereby incorporated by reference into this Item 6. The Subscription Agreements described in Amendment No. 1 provide for certain customary registration rights for the PIPE investors.

None.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 6, 2022

Dated: May 6, 2022

	MOUNT SINAI HEALTH SYSTEM, INC.
	By:	/s/ Stephen Harvey
	Name:  Stephen Harvey
	Title:    Chief Financial Officer Mount Sinai Health System, Inc.

Attention:

Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)